Sign In
Buy AIM
$0.732
-0.0947 (-11.46%)
At Close: Jun 03, 2026
AIM ImmunoTech Announces Cash Conservation Plan
08:00am, Wednesday, 27'th Nov 2024
OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Compensation Committee of the Company's Board of Directors (the “Boar
OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued a presentation in connection with its upcoming 2024 Annual Meeting of Stockholders
Shield Therapeutics ‘on track for 2024' - analyst
09:22am, Thursday, 21'st Nov 2024
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)'s proposed $10 million equity agreement with AOP Health International Management “should provide some much-needed breathing room” for the AIM-listed
OCALA, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data were published on Roswell Park Comprehensive Cancer
AIM ImmunoTech Inc. (AIM) Q3 2024 Earnings Call Transcript
10:32am, Friday, 15'th Nov 2024
AIM ImmunoTech Inc. (NYSE:AIM ) Q3 2024 Earnings Call Transcript November 15, 2024 8:30 AM ET Company Participants Thomas Equels - CEO Christopher McAleer - Scientific Officer Conference Call Particip
AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update
07:29am, Friday, 15'th Nov 2024
– Continued execution across Ampligen® clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space
Aimia Inc. (AIMFF) Q3 2024 Earnings Call Transcript
01:04pm, Friday, 08'th Nov 2024
Aimia Inc. (OTCPK:AIMFF) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants Joe Racanelli - Vice President of Investor Relations Tom Finke - Executive Chairman Steve Leo
AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast
09:00am, Wednesday, 06'th Nov 2024
OCALA, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to di
Pantheon Resources aims to boost profile with US investors
04:17am, Tuesday, 29'th Oct 2024
Pantheon Resources PLC (AIM:PANR, OTCQX:PTHRF) has hired an American investor relations firm as it seeks to woo US investors, ahead of the next wave of progress at the AIM-quoted firm's Alaskan oil an
Inheritance tax raid no death kell for AIM market, says London Stock Exchange exec
04:48am, Friday, 18'th Oct 2024
The potential removal of inheritance tax relief on AIM-listed shares in the upcoming UK Budget has sparked concerns among investors, with many viewing the change as "painful" and "unnecessary". Howeve
First Day of Dealings on AIM and Completion of Fundraise
02:00am, Friday, 18'th Oct 2024
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATE
BitFuFu to Attend AIM Summit Dubai 2024
06:00am, Tuesday, 15'th Oct 2024
SINGAPORE, Oct. 15, 2024 (GLOBE NEWSWIRE) -- BitFuFu Inc., (“BitFuFu” or “the Company”) (NASDAQ: FUFU), a fast-growing digital asset mining service and world-leading cloud-mining service provi
Pulsar Helium to join AIM cashed-up after successful equity raise
04:01am, Tuesday, 15'th Oct 2024
Pulsar Helium Inc (TSXV:PLSR, OTC:PSRHF), an explorer focused on acreage in Minnesota, has confirmed the completion of a £3.88 million (C$7 million) equity raise, ahead of joining the AIM market late
Pulsar Announces a Successful Conditional Fundraising and Publication of an AIM Admission Document
02:00am, Tuesday, 15'th Oct 2024
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATE
AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis
08:45am, Thursday, 03'rd Oct 2024
OCALA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the United States Patent and Trademark Office (USPTO) has
